Inclusion Criteria:

Lead-in safety period:

- Subjects between the age of 18 and 84 years

- Histologically or cytologically confirmed advanced or refractory cholangiocellular
carcinoma, biliary tract cancer, non-small-cell lung carcinoma, duodenal cancer, soft
tissue sarcoma, ovarian carcinoma, or another non-pancreatic cancer disease indicated
for gemcitabine treatment as determined by the investigator

- Subjects who have previously received chemotherapy and standard curative or
palliative care is not available, not effective, or unlikely to be effective

- No option for surgical resection or radiation in curative intent

- Eastern Cooperative Oncology Group (ECOG) performance status assessment of 0 to 2

- Life expectancy of at least 3 months

- No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
lung

- Alanine aminotransferase (ALT) ≤3.0 x upper limit of normal (ULN; ≤5 x ULN for
subjects with liver metastases)

- Aspartate aminotransferase (AST) ≤3.0 x ULN (≤5 x ULN for subjects with liver
involvement with cancer)

- Total bilirubin ≤2.0 x ULN (liver metastasis <5 x ULN)

- Serum creatinine ≤1.5 x ULN

- Adequate bone marrow function: subjects should have an absolute granulocyte count of
at least 1,500 (x 10e6/L) and platelet count of 100,000 (x 10e6/L) prior to the
initiation of a cycle.

- Prothrombin time-international normalized ratio/partial thromboplastin time
(PT-INR/PTT) <1.5 x ULN (subjects who are being therapeutically anti-coagulated with
an agent such as coumadin or heparin will be allowed to participate provided that no
prior evidence of underlying abnormality in these parameters exists). Low-dose
aspirin is permitted (≤100 mg daily).

- Women of childbearing potential must have a negative urine pregnancy test at
baseline.

- Women of childbearing potential and men must be willing to use highly effective
contraceptive methods during the course of the study and 6 months after.

- Subjects must be willing and able (in the opinion of the investigator) to understand
the subject information and informed consent form and to comply with the study
protocol and procedures.

- Subjects must be willing and able to give written informed consent.

Main part:

- Subjects between the age of 18 and 84 years

- Subjects with locally advanced or metastatic pancreatic adenocarcinoma stage III/IV
indicated for gemcitabine treatment as determined by the investigator

- No option for surgical resection or radiation in curative intent

- Histological or cytological documentation of non-hematologic, malignant solid tumor

- At least one measurable lesion or evaluable disease, as per the Response Evaluation
Criteria In Solid Tumors (RECIST) Version 1.1

- Eastern Cooperative Oncology Group (ECOG) performance status assessment of 0 to 2

- Life expectancy of at least 3 months

- No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
lung

- Alanine aminotransferase (ALT) <=3.0 x upper limit of normal (ULN; <=5 x ULN for
subjects with liver metastases)

- Aspartate aminotransferase (AST) <=3.0 x ULN (<=5 x ULN for subjects with liver
involvement with cancer)

- Total bilirubin <=2.0 x ULN (liver metastasis <=5 x ULN)

- Serum creatinine <=1.5 x ULN

- Adequate bone marrow function: subjects should have an absolute granulocyte count of
at least 1,500 (x 10e6/L) and platelet count of 100,000 (x 10e6/L) prior to the
initiation of a cycle.

- Prothrombin time-international normalized ratio/partial thromboplastin time (PT
INR/PTT) <1.5 x ULN (subjects who are being therapeutically anti-coagulated with an
agent such as coumadin or heparin will be allowed to participate provided that no
prior evidence of underlying abnormality in these parameters exists). Low-dose
aspirin is permitted (≤100 mg daily).

- Women of childbearing potential must have a negative urine pregnancy test at
baseline.

- Women of childbearing potential and men must be willing to use highly effective
contraceptive methods during the course of the study and 6 months after.

- Subjects must be willing and able (in the opinion of the investigator) to understand
the subject information and informed consent form and to comply with the study
protocol and procedures.

- Subjects must be willing and able to give written informed consent.

Exclusion Criteria:

Lead-in safety period:

- History of cardiac disease; congestive heart failure >New York Heart Association
(NYHA) functional classification system Class II; active coronary artery disease,
myocardial infarction within 6 months prior to study entry; new onset angina within 3
months prior to study entry or unstable angina, or ventricular cardiac arrhythmias
requiring anti-arrhythmic therapy

- Poorly controlled diabetes defined as hemoglobin A1c (HbA1c) >=7%

- Poorly controlled hypertension, defined as systolic blood pressure >150 mmHg or
diastolic pressure >90 mmHg, despite optimal medical management

- Poorly controlled seizure disorder

- Subjects undergoing renal dialysis

- Known hypersensitivity to the study drugs or active substances or excipients of the
preparations

- Pregnant or breast feeding

- Known hepatitis B or C or human immunodeficiency virus (HIV) infection (if documented
in the subject's record

- Previous participation in this study

- Current or previous (within 30 days of enrolment) treatment with another
investigational drug or participation in another clinical study.

- Subject is a relative of, or staff directly reporting to the investigator.

- Subject is an employee of the sponsor.

- Subject is committed under official or judicial order.

- Any other reason that the investigator considers makes the subject unsuitable to
participate

Main part:

- History of cardiac disease; congestive heart failure >New York Heart Association
(NYHA) functional classification system Class II; active coronary artery disease,
myocardial infarction within 6 months prior to study entry; new onset angina within 3
months prior to study entry or unstable angina, or ventricular cardiac arrhythmias
requiring anti-arrhythmic therapy

- Poorly controlled diabetes defined as hemoglobin A1c (HbA1c) >=7%

- Poorly controlled hypertension, defined as systolic blood pressure >150 mmHg or
diastolic pressure >90 mmHg, despite optimal medical management

- Poorly controlled seizure disorder

- Subjects undergoing renal dialysis

- Anticancer chemotherapy or immunotherapy during the study or before first study
treatment. Subjects with recurrent disease after adjuvant treatment not
progression-free for at least 6 months.

- Radiotherapy to target lesions during study or before study start

- Known hypersensitivity to the study drugs or active substances or excipients of the
preparations

- Pregnant or breast feeding

- Known hepatitis B or C or human immunodeficiency virus (HIV) infection (if documented
in the subject's record

- Previous participation in this study

- Current or previous (within 30 days of enrolment) treatment with another
investigational drug or participation in another clinical study.

- Subject is a relative of, or staff directly reporting to the investigator.

- Subject is an employee of the sponsor.

- Subject is committed under official or judicial order.

- Any other reason that the investigator considers makes the subject unsuitable to
participate